ESMO 2023 Kidney Cancer

Viewing 1-20 of 20 articles

ESMO 2023: State-of-the-Art in Adjuvant Treatment of Renal Cell Carcinoma

ESMO 2023: Comparative Effectiveness of Second Line Treatment with Cabozantinib in Patients with Metastatic Clear Cell RCC after First Line Treatment with Ipilimumab + Nivolumab vs. PD-1/L1 inhibitor + TKI

ESMO 2023: Advances in the Molecular Understanding of GU Cancers: The Next Generation of Therapeutic Targets

ESMO 2023: Prediction of Toxicity in Current Systemic Treatment of Genitourinary Cancers

ESMO 2023: CLEAR Trial, Post Hoc Analysis of the Tumor Response by Baseline Metastases in Patients with Renal Cell Carcinoma Treated with Lenvatinib + Pembrolizumab vs Sunitinib

ESMO 2023: Discussant - MEDI5752 (Volrustomig) for 1st Line Advanced Clear Cell Renal Cell Carcinoma & TIDE-A

ESMO 2023: TIDE-A: Phase II Study of Avelumab plus Intermittent Axitinib in Previously Untreated Patients with mRCC

ESMO 2023: MEDI5752 (Volrustomig), a Novel PD-1/CTLA-4 Bispecific Antibody, in the First-Line Treatment of 65 Patients with Advanced Clear Cell Renal Cell Carcinoma

ESMO 2023: Adjuvant Everolimus in Patients with Completely Resected Very High-Risk RCC and Clear Cell Histology: Results from the Phase III SWOG S0931 (EVEREST) Trial

ESMO 2023: A Pooled Meta-Analysis of Salvage Nivolumab/Ipilimumab after Nivolumab in Patients with Advanced Renal Cell Carcinoma

ESMO 2023: Invited Discussant – RENOTORCH: Toripalimab Combined with Axitinib versus Sunitinib in First-line Treatment of Advanced Renal-Cell Carcinoma: A randomized, Open-label, Phase 3 Study

ESMO 2023: Invited Discussant for LITESPARK-003, LITESPARK-005, and LITESPARK-013

ESMO 2023: RENOTORCH: Toripalimab Combined with Axitinib versus Sunitinib in First-line Treatment of Advanced Renal-Cell Carcinoma: A randomized, Open-label, Phase 3 Study

ESMO 2023: LITESPARK-013 Phase 2- Safety and Efficacy of Two Doses of Belzutifan in Patients with Advanced Renal Cell Carcinoma (RCC)

ESMO 2023: LITESPARK-005 Belzutifan Versus Everolimus in Participants with Previously Treated Advanced Clear Cell Renal Cell Carcinoma: Randomized Open-Label Phase 3

ESMO 2023: STELLAR-304: A Randomized Phase 3 Study of Zanzalintinib (XL092) and Nivolumab in Non-Clear Cell Renal Cell Carcinoma

ESMO 2023: LITESPARK-003 Phase 2 Study of Belzutifan in Combination With Cabozantinib for Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

ESMO 2023: New Therapeutic Targets in Advanced Renal Cell Carcinoma (RCC) and Data from Sequencing Trials

ESMO 2023: What is the Role of Localized Therapies in Metastatic Renal Cell Carcinoma (RCC)?

ESMO 2023: Evolving Frontline Treatment Paradigms in Advanced Renal Cell Carcinoma